



**ASF GROUP LIMITED**

**ACN 008 924 570**

Bennelong, 2/3B Macquarie Street  
Sydney NSW 2000

Telephone: (61 2) 9251 9088

Facsimile: (61 2) 9251 9066

[www.asfgroupltd.com](http://www.asfgroupltd.com)

13 August 2019

The Manager  
Company Announcements  
Australian Securities Exchange  
20 Bridge Street  
Sydney NSW 2000  
via: [www.asxonline.com](http://www.asxonline.com)

Dear Sir/Madam

**ASF Biotech Investment in the UK**

ASF Group Limited (ASX:AFA) is pleased to advise that it has invested into an exciting new biotech opportunity being commercialised from intellectual property (“IP”) developed by Prof. Che Connon from Newcastle University, UK.

The ground-breaking biotech IP won the 2018 London Medical Design Gold Award and comprise a method wherein stem cell derived corneal collagen production via 3D printed constructs create improved corneal function in human cornea transplants.

The investors including Newcastle University, Prof. Connon, and ASF will form a company to be called 3D Bio-Tissues Ltd. (“**3DBT**”) for In Vivo Phases & animal trials of the IP. ASF is investing into 3DBT over time to take its investment up to 49% equity interest.

We will keep the market informed of developments in due course.

***Information about ASF***

ASF Group Limited (ASX: AFA) is unique among ASX-listed public companies as it powers business between the East and West. ASF is an investment and trading house which focuses principally on the identification, incubation and realization of opportunities in areas of synergy between China, Australia, UK and Europe including technology, oil & gas, resources, property, infrastructure, travel and financial services sectors.

Geoff Baker  
Director  
ASF Group Ltd  
Ph: +612 9251 9088